Preclinical evaluation of JAK2 specific investigational oligonucleotide for the treatment of MDS/PV.

Authors

null

Bartlomiej Przychodzen

Vanda Pharmaceuticals Inc., Washington, DC

Bartlomiej Przychodzen , Sandra Paulina Smieszek

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics

Sub Track

Targeted Therapies

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 122)

DOI

10.1200/GO.2023.9.Supplement_1.122

Abstract #

122

Poster Bd #

F5

Abstract Disclosures

Similar Posters

First Author: Eleonora Teplinsky

Poster

2013 ASCO Annual Meeting

Identification of pSTAT5 gene signature in hematologic malignancy.

Identification of pSTAT5 gene signature in hematologic malignancy.

First Author: Dmitriy Sonkin

First Author: S. Verstovsek